Oral BioLife, a technology company focused on non-invasive therapies to restore bone and soft tissue, has appointed Greg Ambra as CEO and Tim Glennon as chief commercialization officer.
Mr. Ambra has nearly 30 years of experience leading clinical development, operations and commercialization, according to a Sept. 15 news release.
Mr. Glennon joins the company with expertise in investor relations, corporate strategy and product commercialization, including the launch of more than 15 medical devices and drugs.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place September 14-15 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
